<DOC>
	<DOCNO>NCT00050349</DOCNO>
	<brief_summary>This study examine whether new investigational drug EPO906 , give intravenous infusion ( IV directly vein ) , effective shrinking tumor prevent growth cell cause metastatic carcinoid neuroendocrine tumor .</brief_summary>
	<brief_title>EPO906 Carcinoid Other Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>Patients biopsyproven metastatic carcinoid tumor neuroendocrine tumor ( Islet cell , Gastrinomas VIPomas ) least one measurable lesion ( bone ) either previously irradiate previously irradiate demonstrate progression since radiation therapy The patient major impairment renal hepatic function , define follow laboratory parameter : total bilirubin &lt; 1.5 X ULN ; AST , ALT &lt; 2.5X ULN ( &lt; 5 X ULN liver metastasis present ) Patients Sandostatin Lar ( long act somatostatin analogue ) must stable dose 30 day prior study entry short act somatostatin analogue must judge clinically stable dose investigator prior study entry Must life expectancy great three ( 3 ) month Karnofsky Performance Status &gt; 60 Female patient must negative serum pregnancy test screening . ( Not applicable patient bilateral oophorectomy and/or hysterectomy patient postmenopausal . ) Patients symptomatic CNS metastasis leptomeningeal involvement Patients know brain metastasis , unless metastasis treat and/or stable least six month prior study start . Subjects history brain metastasis must head CT contrast document either response progression . Patients bone metastasis site ( ) measurable disease Patients hepatic artery chemoembolization within last 6 month ( one month sit measurable disease ) Patients previously treat radioactive directed therapy Patients previously treat epothilone Patients peripheral neuropathy unresolved diarrhea great Grade 1 Patients severe cardiac insufficiency patient take Coumadin warfarincontaining agent exception low dose warfarin ( 1 mg less ) maintenance indwell line port Patients take experimental therapy history another malignancy within 5 year prior study entry except curatively treat nonmelanoma skin cancer , prostate cancer , cervical cancer situ Patients active suspect acute chronic uncontrolled infection include abcesses fistulae Patients medical psychiatric illness would preclude study informed consent and/or history noncompliance medical regimen inability unwillingness return schedule visit HIV+ patient Pregnant lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>cancer</keyword>
	<keyword>tumor</keyword>
	<keyword>tumour</keyword>
	<keyword>neoplasm</keyword>
	<keyword>carcinoma</keyword>
	<keyword>carcinoid</keyword>
	<keyword>neuroendocrine</keyword>
	<keyword>Islet cell</keyword>
	<keyword>Gastrinoma</keyword>
	<keyword>VIPoma</keyword>
	<keyword>metastatic</keyword>
	<keyword>intravenous</keyword>
	<keyword>epothilone</keyword>
</DOC>